IMAGING TUMOR VARIATION IN RESPONSE TO PHOTODYNAMIC THERAPY IN PANCREATIC CANCER XENOGRAFT MODELS

被引:46
|
作者
Samkoe, Kimberley S. [1 ]
Chen, Alina [1 ]
Rizvi, Imran [1 ,2 ]
O'Hara, Julia A. [1 ]
Hoopes, P. Jack [1 ,3 ]
Pereira, Stephen P. [4 ]
Hasan, Tayyaba [2 ]
Pogue, Brian W. [1 ,2 ,3 ]
机构
[1] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03766 USA
[2] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA
[3] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Surg, Hanover, NH 03756 USA
[4] UCL, Sch Med, Inst Hepatol, London W1N 8AA, England
基金
美国国家卫生研究院;
关键词
Photodynamic therapy; Pancreatic cancer; Magnetic resonance imaging; Tumor aggressiveness; Orthotopic tumor; ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN; ADENOCARCINOMA; GEMCITABINE;
D O I
10.1016/j.ijrobp.2009.08.041
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A treatment monitoring study investigated the differential effects of orthotopic pancreatic cancer models in response to interstitial photodynamic therapy (PDT), and the validity of using magnetic resonance imaging as a surrogate measure of response was assessed. Methods and Materials: Different orthotopic pancreatic cancer xenograft models (AsPC-1 and Panc-1) were used to represent the range of pathophysiology observed in human beings. Identical dose escalation studies (10, 20, and 40J/cm) using interstitial verteporfin PDT were performed, and magnetic resonance imaging with T2-weighted and T1-weighted contrast were used to monitor the total tumor volume and the vascular perfusion volume, respectively. Results: There was a significant amount of necrosis in the slower-growing Panc-1 tumor using high light dose, although complete necrosis was not observed. Lower doses were required for the same level of tumor kill in the faster-growing AsPC-1 cell line. Conclusions: The tumor growth rate and vascular pattern of the tumor affect the optimal PDT treatment regimen, with faster-growing tumors being relatively easier to treat. This highlights the fact that therapy in human beings shows a heterogeneous range of outcomes, and suggests a need for careful individualized treatment outcomes assessment in clinical work. (C) 2010 Elsevier Inc.
引用
收藏
页码:251 / 259
页数:9
相关论文
共 50 条
  • [31] Construction of orthotopic xenograft mouse models for human pancreatic cancer
    Dai, Lei
    Lu, Caide
    Yu, Xi
    Dai, Long-Jun
    Zhou, Jeff X.
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 10 (03) : 1033 - 1038
  • [32] Photodynamic therapy and tumor imaging without a light source
    Bossmann, Stefan H.
    Shrestha, Tej B.
    Samarakoon, Thilani N.
    Basel, Matthew T.
    Balivada, Sivasai
    Alshetaiwi, Hamad
    Giri, Dipak
    Wang, Hongwang
    Higgins, Daniel A.
    Troyer, Deryl L.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [33] Phthalocyanine labeled LDL for tumor imaging and photodynamic therapy
    Li, H
    Marotta, D
    Kim, SK
    Chance, B
    Glickson, J
    Busch, TM
    Zheng, G
    OPTICS IN HEALTH CARE AND BIOMEDICAL OPTICS: DIAGNOSTICS AND TREATMENT II , PTS 1 AND 2, 2005, 5630 : 8 - 15
  • [34] The role of porphyrin chemistry in tumor imaging and photodynamic therapy
    Ethirajan, Manivannan
    Chen, Yihui
    Joshi, Penny
    Pandey, Ravindra K.
    CHEMICAL SOCIETY REVIEWS, 2011, 40 (01) : 340 - 362
  • [35] A Theranostic Nanoprobe for Hypoxia Imaging and Photodynamic Tumor Therapy
    Fan, Jing Hao
    Fan, Gui Ling
    Yuan, Ping
    Deng, Fu An
    Liu, Ling Shan
    Zhou, Xiang
    Yu, Xi Yong
    Cheng, Hong
    Li, Shi Ying
    FRONTIERS IN CHEMISTRY, 2019, 7
  • [36] Photodynamic therapy enables tumor-specific ablation in preclinical models of thyroid cancer
    Muhanna, Nidal
    Chan, Harley H. L.
    Townson, Jason L.
    Jin, Cheng S.
    Ding, Lili
    Valic, Michael S.
    Douglas, Catriona M.
    MacLaughlin, Christina M.
    Chen, Juan
    Zheng, Gang
    Irish, Jonathan C.
    ENDOCRINE-RELATED CANCER, 2020, 27 (02) : 41 - 53
  • [37] Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
    Peng, June S.
    Wey, Jane
    Chalikonda, Sricharan
    Allende, Daniela S.
    Walsh, R. Matthew
    Morris-Stiff, Gareth
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2019, 18 (04) : 373 - 378
  • [38] Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
    Stefan Heinrich
    Hepatobiliary&PancreaticDiseasesInternational, 2019, 18 (04) : 305 - 306
  • [39] Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
    Heinrich, Stefan
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2019, 18 (04) : 305 - 306
  • [40] Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
    June S Peng
    Jane Wey
    Sricharan Chalikonda
    Daniela S Allende
    R Matthew Walsh
    Gareth Morris-Stiff
    Hepatobiliary&PancreaticDiseasesInternational, 2019, 18 (04) : 373 - 378